Site specificity determinants for prelamin A cleavage by the zinc metalloprotease ZMPSTE24

Received for publication, August 27, 2020, and in revised form, November 23, 2020. Published, Papers in Press, December 8, 2020, https://doi.org/10.1074/jbc.RA120.015792

Timothy D. Babatz, Eric D. Spear, Wenxin Xu, Olivia L. Sun, Laiyin Nie, Elisabeth P. Carpenter, and Susan Michaelis

From the 1Department of Cell Biology, The Johns Hopkins School of Medicine, Baltimore Maryland, USA; 2Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford, UK

Edited by Peter Cresswell

The integral membrane zinc metalloprotease ZMPSTE24 is important for human health and longevity. ZMPSTE24 performs a key proteolytic step in maturation of prelamin A, the farnesylated precursor of the nuclear scaffold protein lamin A. Mutations in the genes encoding either prelamin A or ZMPSTE24 that prevent cleavage cause the premature aging disease Hutchinson–Gilford progeria syndrome (HGPS) and related progeroid disorders. ZMPSTE24 has a novel structure, with seven transmembrane spans that form a large water-filled membrane chamber whose catalytic site faces the chamber interior. Prelamin A is the only known mammalian substrate for ZMPSTE24; however, the basis of this specificity remains unclear. To define the sequence requirements for ZMPSTE24 cleavage, we mutagenized the eight residues flanking the prelamin A scissile bond (TRSYLLGN) to all other 19 amino acids, creating a library of 152 variants. We also replaced these eight residues with sequences derived from putative ZMPSTE24 cleavage sites from amphibian, bird, and fish prelamin A. Cleavage of prelamin A variants was assessed using an in vivo yeast assay that provides a sensitive measure of ZMPSTE24 processing efficiency. We found that residues on the C-terminal side of the cleavage site are most sensitive to changes. Consistent with other zinc metalloproteases, including thermolysin, ZMPSTE24 preferred hydrophobic residues at the P1’ position (Leu647), but in addition, showed a similar, albeit muted, pattern at P2’. Our findings begin to define a consensus sequence for ZMPSTE24 that helps to clarify how this physiologically important protease functions and may ultimately lead to identifying additional substrates.

Proteases play key roles in diverse biological processes relevant to human health and disease. Defining their substrate cleavage specificity is essential to fully understand protease physiological function (1, 2). ZMPSTE24 is a zinc metalloprotease that is critical for the proteolytic maturation of lamin A, an intermediate filament protein and component of the nuclear lamina (3–9). The lamin A precursor, prelamin A, encoded by the LMNA gene, undergoes processing at its C-terminal CAAX motif (C is cysteine, A is usually an aliphatic residue, and X is any amino acid). CAAX processing includes farnesylation of the cysteine residue, endoproteolytic cleavage of the C-terminal tripeptide (-AAX), and carboxyl methylylation of the farnesylated cysteine (10–13). Subsequently, ZMPSTE24 proteolytically removes a C-terminal segment of prelamin A, including the farnesylated cysteine, by cleavage between residues Y646 and L647 to produce mature lamin A (3, 9, 14, 15) (Fig. 1A).

Lack of this ZMPSTE24 cleavage event due to mutations in the LMNA or ZMPSTE24 genes results in accumulation of permanently farnesylated and carboxyl methylated prelamin A, which causes progeroid diseases (8, 16–18). The premature aging disorder Hutchinson–Gilford progeria syndrome (HGPS) is due to a LMNA splicing mutation that deletes 50 amino acids from prelamin A, including the ZMPSTE24 processing site (8, 19–21). The related progeroid diseases mandibuloacral dysplasia type-B (MAD-B) and restrictive dermopathy (RD) are caused by ZMPSTE24 mutations (22–26). Disease severity appears to correlate with the extent of ZMPSTE24’s deficiency in cleaving prelamin A (27, 28). Some evidence suggests that decreased expression or activity of ZMPSTE24, resulting in the accumulation of prelamin A, may also contribute to normal physiological aging (29).

ZMPSTE24, like its yeast counterpart Ste24, is a multi-spanning membrane protease with its active site zinc and catalytic residues located inside of a large enclosed water-filled chamber in the membrane created by seven transmembrane spans (30, 31). Like other metalloproteases of the gluzincin family, including soluble thermolysin, ZMPSTE24/Ste24 contains an HEXXH motif (31–35). The HEXXH glutamate activates a water molecule for hydrolysis of the scissile bond and the two histidines (along with a glutamate outside of the HEXXH motif) coordinate the zinc atom. ZMPSTE24 is sometimes classified as an intramembrane protease (36), although others argue against this classification since, unlike rhomboids and other intramembrane proteases that cleave substrates within the lipid bilayer, ZMPSTE24/Ste24
substances are cleaved within the aqueous environment of the membrane-embedded chamber where the catalytic domain resides (34, 37). The exact mechanism by which the prelamin A substrate reaches the ZMPSTE24 interior remains unknown; however, the fenestrations observed in the human ZMPSTE24 and yeast Ste24 crystal structures could provide access (30, 31). Furthermore, prelamin A is likely too large (~74 kD) to fit entirely within the catalytic chamber, suggesting that only the farnesylated C-terminal domain of prelamin A must be threaded into the chamber for cleavage.

The substrate specificity and cleavage site determinants for ZMPSTE24/Ste24 have not been well characterized. To date only two specific in vivo substrates are known, mammalian prelamin A and yeast a-factor, respectively, and both are farnesylated (11, 38). Studies in vivo and in vitro have shown that yeast Ste24 can mediate two cleavage steps for a-factor: endoproteolytic removal of the—AAX residues of the CAAX motif CVIA (in which Ste24 plays a redundant role with another protease, Rce1), and a key upstream cleavage between residues T7 and A8—which Ste24 performs uniquely (39–44). ZMPSTE24 cleaves prelamin A at the upstream site between Y646 and L647, discussed above. While a role for ZMPSTE24 in removal of the—AAX residues of the prelamin A CAAX motif in redundancy with Rce1 has often been suggested, recent evidence suggests that ZMPSTE24 may only poorly cleave the CAAX motif (CSIM) of prelamin A (45).

It is notable that both known substrates for ZMPSTE24/Ste24, prelamin A and a-factor, are farnesylated. In vivo, farnesylation is absolutely required for cleavage of both (14, 40, 42, 46–49). However, in vitro, farnesylated prelamin A peptides are cleaved properly, but imperfect cleavage events are also observed for nonfarnesylated peptides indicating that farnesyl contributes mainly to protecting cells against enveloped viruses; however, its role in this process remains enigmatic since catalytic activity appears to be dispensable for this function (54, 55).

Apart from the known scissile bond cleaved by ZMPSTE24 in prelamin A (between Y646 and L647) (14, 15, 56), and by Ste24 in yeast a-factor (between T7 and A8) (40, 42), there is limited information about the rules governing substrate cleavage. Studies of numerous proteases have employed peptide libraries with variants surrounding the scissile bond, in conjunction with quantitative mass spectrometry to classify the
efficiency of various residues for substrate cleavage (57, 58). However, the requirement of prelamin A farnesylation for optimal cleavage by ZMPSTE24, along with the difficulty of synthesizing prenylated peptides, and the challenges of purifying and maintaining activity of ZMPSTE24 as a multispanning membrane protein introduce several technical challenges that make in vitro approaches less than ideal. Here, we used a variation of our previously characterized humanized yeast assay (28, 59) to define the rules of allowable substitutions at each of the eight residues flanking the prelamin A cleavage site in order to gain information about how the enzyme works, to assess potential prelamin A disease alleles, as well as to eventually help to identify other putative ZMPSTE24/Ste24 substrates.

Results
A humanized yeast system for analysis of ZMPSTE24 cleavage of prelamin A

We previously demonstrated that expression of human ZMPSTE24 together with the C terminus of human prelamin A in a yeast strain deleted for endogenous STE24 (ste24Δ) provides an ideal model system for studying lamin A maturation in vivo (28, 59). The initial steps of lamin A biogenesis are mediated by the yeast CAAX processing machinery, resulting in a farnesylated, carboxymethylated prelamin A substrate (Fig. 1A). The humanized yeast system used in the present study (called version 2.0) is shown in Fig. 1B. It features Myc-tagged prelamin A (residues 431–664) expressed from a plasmid in a yeast ste24Δ strain background with chromosomally integrated HA-tagged ZMPSTE24 (Fig. 1B). Western blotting shows that cleavage of the prelamin A substrate is dependent on the presence of ZMPSTE24, and at steady state, approximately 80–90% of the substrate is in the mature lamin A form (Fig. 1C). This version 2.0 humanized yeast system is ideal for maintaining consistent expression of ZMPSTE24, due to its chromosomal integration, while allowing easy introduction by plasmid transduction of a large collection of prelamin A mutants. This contrasts with our previously described system (version 1.0) optimized to study disease alleles of ZMPSTE24; in that case LMNA was chromosomally integrated and plasmids bore the mutant forms of ZMPSTE24 (28, 59).

Comprehensive scanning mutagenesis of the prelamin A cleavage site

The cleavage site specificity for a protease can potentially involve residues both N- and C-terminal to the scissile bond. To methodically survey the importance of residues flanking the prelamin A cleavage site, we mutagenized residues in the P4–P4’ positions shown in Figure 1A to all of the other 19 amino acids. (We use the standard nomenclature of Berger and Schechter (60) in which the unprimed and primed residues refer to the N- and C-terminal sides of the scissile bond respectively, with cleavage occurring between P1 and P1’). This allowed us to assay all 20 possible residues at positions P4–P4’ for cleavage of prelamin A. Plasmids expressing individual prelamin A variants were transformed into the ZMPSTE24-expressing strain SM6303, and the steady-state cleavage efficiency in cells was calculated as a ratio between processed (mature) and total (unprocessed + processed) signal. In all experiments, the wild-type (WT) residue and 19 mutants were assayed in parallel, and cleavage efficiency relative to WT (set to 100%) was determined. Three independently grown replicate cultures were tested for each variant. Results for mutations N-terminal to the cleavage site (residues P1–P4) are shown in Figure 2, and for mutations C-terminal to the cleavage site (residues P1’–P4’) in Figure 3. (See also the heatmap in Figure 4.) This analysis reveals several important insights that are discussed below.

For the most distal residues (P4 and P4’), only a few mutants showed effects on cleavage, and none of these were dramatic (Figures 2 and 3). Changes in T643 (the P4 position) to almost any other amino acid had little effect on substrate cleavage (Fig. 2A). Even the strongest mutants (T643D, E and N) still retained significant cleavage of at least 60% compared with the WT allele. Similarly, the P4’ position (N650) is also largely insensitive to changes, with no mutants reducing cleavage to less than 60% (Fig. 3D). Together, these data suggest that the cleavage site recognition motif is generally defined by positions P3 to P3’.

N-terminal to the scissile bond, at positions P3–P1, substitutions to aspartate, glutamate, valine, isoleucine, and tryptophan disrupt prelamin A cleavage, showing minor to severe disruptions depending on the residue queried (Fig. 2, B–D). Just N-terminal to the scissile bond at position P1 (Y646), substitutions that change the aromatic residue tyrosine to the aliphatic residues isoleucine or valine impaired cleavage significantly (>50%), while other substitutions showed mild or no effects. At P2 (S645), only a single substitution to aspartate reduced cleavage to lower than 50%. In contrast, the arginine at position P3 (R644) is the most sensitive to substitution, with the negatively charged residues aspartate and glutamate, the hydrophobic residues isoleucine, leucine, tyrosine, and particularly tryptophan disrupting cleavage significantly to <30% residual activity; (Fig. 2B). Many other R644 substitutions also showed effects on cleavage efficiency, albeit modest (<20% reduction of cleavage). This residue is of particular interest because of the association of R644 mutations with diverse laminopathy disease phenotypes (61) and is discussed further below. Taken together only a few scattered substitutions in the P3–P1 residues N-terminal to the scissile bond of prelamin A showed significant processing defects, but no strong pattern for substrate cleavage requirements in this region was evident.

In contrast to residues N-terminal to the cleavage site, residues C-terminal to the cleavage site at the P1’–P3’ were more sensitive to mutation, especially at the P1’ and P2’ positions, and preference patterns were evident (Fig. 3, A–C; see also Fig. 4). Leucines at positions P1’ and P2’ emerged as critical to ZMPSTE24 processing of prelamin A, with hydrophobic residues strongly preferred at these positions (with the exception of bulky aromatics tyrosine and tryptophan for L647). (Fig. 3, A–B). Consistent with previous studies (28, 48, 56), the L647 R mutation decreased cleavage efficiency to about 5% relative to WT (Fig. 3A). L647 R has long been
Figure 2. Comprehensive scanning mutagenesis of positions P4–P1 in prelamin A, changing to all other 19 amino acids. Western blots for all possible variants of residues T643 (A), R644 (B), S645 (C), and Y646 (D) are shown. Uncleaved prelamin A (empty arrowhead) and mature lamin A (filled arrowhead) are indicated. For each residue, wild-type (WT) is indicated in red. Residues are color-coded as indicated. Cleavage efficiency is calculated by dividing mature lamin A by total lamin A abundance (cleaved + uncleaved). WT for each residue is normalized to 1 and all mutants are plotted relative to it. Three biological replicates were performed for each mutant. Asterisks by the residue name indicate mutations in which processing is statistically significantly different than WT, Student's t-test, two-tailed, unpaired, N = 3.
known to disrupt processing and has been reported in a patient with a progeroid disorder (62). Our comprehensive mutagenesis shows that all other charged residues, as well as polar residues, proline, and glycine, nearly abolish processing at L647. L648 shows a very similar pattern, albeit more muted (Fig. 3B and 4), with several notable differences. The bulky aromatic hydrophobic residues tyrosine and tryptophan that are disruptive at L647 (P1') are tolerated at L648 (P2'). Substitution with alanine is tolerated at L647, but disruptive at L648, which had been observed previously in a limited mutagenesis scan in mammalian cells (63). Substitutions of proline and glycine at both L647 and L648 largely abolish ZMPSTE24

**Figure 3. Comprehensive scanning mutagenesis of positions P1’–P4’ in prelamin A to all other 19 amino acids.** Western blots for all possible variants of residues L647 (A), L648 (B), G649 (C), and N650 (D), are shown. For each residue, WT is indicated in red. Annotation of uncleaved and mature lamin A, quantification of cleavage, and statistical analysis are performed as explained in the legend for Figure 2.
Cleavage site for prelamin A processing by ZMPSTE24

Using the cleavage data from Figures 2 and 3, we constructed a heatmap of cleavage efficiency for the prelamin A residues tested to further help detect patterns (Fig. 4). Generally, it is evident from the darker shades in the heatmap that the C-terminal side of the cleavage site (P1’–P3’) is far more sensitive to mutation than the N-terminal side (P3–P1) and that the P4 and P4’ positions show low preference for specific residues. No mutations to the N-terminal side of the cleavage site completely abolish processing, while many C-terminal mutations do. However, the severity of two changes at changes at P1 (Y646 V and Y646I) and several at P3 (R644D, E, I, L, Y, W) are notable. As shown for other zinc metalloproteases, a hydrophobic amino acid at the P1’ position is strongly preferred by ZMPSTE24 (with the exception of tyrosine or tryptophan), which fits with the previous suggestion that the proposed S1′ binding pocket in ZMPSTE24 may be a hydrophobic patch (31). In contrast to other metalloproteases, ZMPSTE24 also appears to prefer a hydrophobic residue at P2’, suggesting an extended hydrophobic patch that encompasses both S1’ and S2’.

Multiple evolutionarily conserved substitutions at the prelamin A cleavage site are tolerated by ZMPSTE24

In the comprehensive mutational analysis above, we analyzed only one amino acid change at a time. However, an inherent limitation of this analysis is that multiple residues within the tested region may show “subsite cooperativity,” with either positive or negative effects on activity, as has been observed for the HIV-1 protease and others (64–66). Because we were also interested in whether multiple combinatorial amino acid substitutions at the prelamin A cleavage site would be tolerated by ZMPSTE24, we turned to evolutionary information. The LMNA gene shows significant conservation throughout vertebrates. We performed a protein sequence alignment for several mammals, birds, fish, and amphibians, which indicated evolutionary conservation of the C-terminus of prelamin A (Fig. 5A). The CAAX motif is highly conserved through species, with the farnesylated cysteine invariantly four residues from the C-terminus for all species and a CAAX consensus sequence of C-S-I/V-M. However, there was a marked degree of variation in the residues surrounding the predicted ZMPSTE24 cleavage site, ranging from three to seven amino acid differences from human LMNA, depending on the species (Fig. 5B, see residues in red). (It should be noted that only human, mouse, and chicken prelamin A have definitively been shown to be processed (3, 9, 49, 56)). Importantly, all species had hydrophobic residues in the critical P1’ and P2’ residues just C-terminal to the cleavage site and generally conform to the rules of the heatmap in Figure 4.

To ascertain the extent to which human ZMPSTE24 can cleave these divergent putative cleavage sites, we introduced amino acid substitutions in positions P4 through P4’ into our prelamin A expression construct to recapitulate the putative cleavage sites observed in the multispecies alignment. In the cleavage assay, all of the putative prelamin A cleavage sites were recognized and processed by ZMPSTE24, most with only protein processing, while these substitutions are well tolerated at all other positions flanking the cleavage site.

We note that some substitution mutations in both the primed and unprimed positions (i.e., Y646 V, I and G649 V, I, L) showed a low amount of total (unprocessed + processed) signal, possibly due to impaired translatability or RNA stability stemming from poor codon usage or aberrant mRNA structure. However, this did not appear to impact cleavability per se and attempts to change several of these substitutions to optimal codons for yeast did not increase the amount or alter extent of cleavage. It is also possible that these versions of prelamin A are degraded; however, we found that proteasome inhibitors did not increase their amounts (data not shown).

Figure 4. Heatmap showing the ZMPSTE24 cleavage efficiency for every individual amino acid substitution in residues P4–P4’. The P4–P4’ region surrounding the prelamin A cleavage site was comprehensively interrogated by positional scanning mutagenesis, as shown in Figures 2 and 3. The effects of individual amino acid substitutions at each site were scored relative to WT at 100% cleavage efficiency and assigned into ten bins. Residues are shaded in accordance with cleavage efficiency, ranging from WT level of cleavage (white) to poor or no cleavage (black).
modest differences relative to the human cleavage site TRSY1LLGN (70–90%) (Fig. 5B). The zebrafish sequence, with seven of the eight cleavage site residues substituted, was the only one with a statistically significant defect, although even in this case a substantial amount of cleavage (>50%) did occur. Thus, it appears that ZMPSTE24 can tolerate multiple substitutions at the cleavage site, so long as the changes conform to the rules defined by the heatmap data of Figure 4.

Discussion

Here we have used a humanized yeast assay to determine the impact of amino acid substitutions in residues P4–P4’ surrounding the scissile bond of prelamin A for cleavage by ZMPSTE24. ZMPSTE24-dependent prelamin A processing in vivo is completely dependent on farnesylation (14, 46–49). Farnesyl may be needed to deliver the substrate to membrane-embedded ZMPSTE24 and/or to engage a potential exosite inside or outside of the enzyme chamber. In the current work, the native yeast farnesyltransferase (the Ram1/Ram2 heterodimer), along with the yeast CAAX processing enzymes Rce1 and Ste14 (11) generates a suitable farnesylated substrate for ZMPSTE24. This system has allowed us to interrogate a comprehensive library of farnesylated substrates for ZMPSTE24 cleavage.

Screening our collection of 152 cleavage site mutants in this in vivo assay yielded a heatmap of cleavage efficiency (Fig. 4). In general, P1’ (Leu647) and P2’ (Leu648) were the most sensitive residues to perturbations, specifically alterations to nonhydrophobic mutations (Fig. 3, A–B). This is similar to, but distinct from, the related protease thermolysin, which requires aliphatic or aromatic residues at P1’ but does not have a known preference at position P2’ (58). While substitutions at a few other positions of prelamin A (see below) diminish processing, almost none have as strong an effect as those at P1’ or P2’. At the outset of this study we knew that the P1’ position was critical for prelamin A cleavage, since the L647 R mutation severely reduced prelamin A processing in cell-based experiments and a recently reported MAD-B patient (12, 28, 48, 56, 63). Here we found that no charged residues are allowable at P1’ and that hydrophobic residues are strongly preferred, except for the large aromatic residues tryptophan and tyrosine. Notably P2’ had similar requirements to P1’ although the negative effect of many substitutions at this position was generally diminished as compared with the same substitution at P1’.

To understand the potential impact of specific prelamin A mutations, we modeled the prelamin A tetrapeptide SY1LL, which contains the scissile bond and is comprised of residues P2–P2’, into the ZMPSTE24 cleavage site, based on our previously published structure of ZMPSTE24 and the CSIM tetrapeptide (PDB:2YPT) (31) (Fig. 6, A–C). The S1’ hydrophobic binding pocket is composed of Val332 and Leu283 and would not be expected to permit charged residues at P1’, just as we observed. The pocket is large enough to accommodate a large hydrophobic residue like phenylalanine, but not tryptophan. However, unlike L647F, L647Y could not be cleaved by ZMPSTE24. The reason probably lies in the difference between the abilities of tyrosine and phenylalanine to form hydrogen bonds. Hydrogen bonding by tyrosine with a nearby polar residue of ZMPSTE24 at the catalytic site could interfere with the catalytic reaction, which involves the attack of a water molecule on the carbonyl carbon of the scissile peptide bond. Indeed, substitution of Leu647 to any amino acid that can form a hydrogen bond resulted in poor cleavage efficiency.

---

**Figure 5. Multispecies analysis of ZMPSTE24-dependent cleavage of prelamin A.** A, Multispecies alignment of the amino acid sequence of the C terminus of prelamin A. The inferred prelamin A cleavage site and CAAX motif are indicated. Black shading indicates identity and gray shading indicates similarity. B, Western blots for inferred multispecies variants of the prelamin A cleavage site. Amino acid substitutions representing each species for P4–P4’ were made in plasmid pSM3393, as indicated above the western blot with differences from human prelamin A (left) highlighted in red. The white and gray boxes under the residues are in accordance with the Figure 4 heatmap. Uncleaved prelamin A (empty arrowhead) and mature lamin A (filled arrowhead) are indicated. Each construct was assayed with (+) and without (−) ZMPSTE24 coexpression. Quantification was performed as in previous figures. The zebrafish sequence was the only divergent cleavage site with a statistically significant cleavage defect (p < 0.05, Student’s t-test, two-tailed, unpaired, N = 3) and is marked with an asterisk.
Cleavage site for prelamin A processing by ZMPSTE24

The predicted S2′ binding pocket has a hydrophobic surface formed by the sidechain of Leu438 (Fig. 6, B–C), consistent with our findings that at P2′ hydrophobic residues are also preferred. Poor cleavage of polar and charged residues in the P2′ position might be due to their hydrogen bonding with the nearby Asn442, resulting in misalignment of the substrate. In addition to the hydrophobic nature of the S1′ and S2′ binding pockets of ZMPSTE24, Leu647 and Leu648 on the prelamin A peptide contribute to the hydrophobic environment in this region. Consequently, a change of either residue to a more polar or charged side chain is predicted to reduce the strength of the interaction of the adjacent side chain. Similarly, a proline residue in this region would not only disrupt the interactions of that side chain, it would also misalign the side chain of the adjacent residue, thus explaining the failure of cleavage with proline at either P1′ and P2′ sites.

The data presented here align with the few other studies performed to date on substrate specificity of ZMPSTE24/Ste24. Though not comprehensive, in a random mutagenesis screen for mutations that decreased yeast a-factor cleavage by Ste24 between residues T7 and A8 (at TATAAP), substitutions to the nonhydrophobic residues glycine or threonine at P1′ and proline at P2′ all blocked a-factor upstream processing (42). Purified Ste24 has been shown to correctly perform −AAX removal of a synthetic farnesylated a-factor 15-mer substrate using the native farnesylated a-factor CAAX motif f-CVIA (44), which conforms to the rule of hydrophobic residues at P1′ and P2′ (valine and isoleucine, respectively). Surprisingly, ZMPSTE24-dependent cleavage of the natural prelamin A CAAX sequence, f-CSIM, in the context of a farnesylated 29mer prelamin A peptide produced mostly a dipeptide, −IM, instead of the −SIM tripeptide expected for authentic −AAX cleavage (31, 45). However, when the CAAX motif was changed to the Ras-derived sequence CAAX motif, farnesylated-CVLS, ZMPSTE24 produced a correctly −AAxed tripeptide, −VLS, highlighting the preference of the protease for hydrophobic residues (valine and leucine in this case) at the P1′ and P2′ positions (45).

ZMPSTE24 is able to recognize and cleave evolutionarily divergent P4′−P4′ cleavage sites in prelamin A sequences obtained from several species (Fig. 5). Although prelamin A processing has only been directly demonstrated for human, mouse, and chicken homologs, the strong similarity observed in alignments of the C-terminal portion of prelamin A for numerous vertebrate sequences suggests that ZMPSTE24 processing is likely to be a shared feature among all species. None of the residues flanking these putative cleavage sites (Fig. 5) violate the rules defined by our heatmap. All have “allowable” hydrophobic residues at the inferred P1′ and P2′ sites, and indeed all were cleaved when placed into the context of prelamin A at a level 50–100% that of WT. While the rules established in this study are unlikely to be specific enough to be predictive of possible substrates (i.e., to propose a strict consensus motif), it is notable that human ZMPSTE24 could recognize and cleave several divergent substrate sequences that conform to the rules indicated by the heatmap.

Although substrate farnesylation increases both efficiency and fidelity of cleavage, it is not an absolute requirement for ZMPSTE24/Ste24-dependent processing in vitro (31, 45). Along these lines, yeast Ste24 has been shown to cleave non-farnesylated substrates unrelated in sequence to prelamin A or a-factor, including an M16 A protease reporter and an insulin B-chain. Mass spectrometry analysis of cleavage products revealed that the P1′ and P2′ sites chosen within these substrates for cleavage by Ste24 in vitro were hydrophobic in nature (50). While translocon clogger substrates have not yet been evaluated in terms of their ZMPSTE24-dependent cleavage products, it would be of interest to analyze these products by mass spectrometry.

We also observed in this study that the arginine at position P3 is sensitive to substitution. Negatively charged residues, hydrophobic residues, and particularly tryptophan, all diminished cleavage. This residue is of particular interest because of the association of variant R644C with diverse human disease phenotypes including cardiovascular disease, muscular dystrophy, and skeletal abnormalities. This variant shows...
incomplete penetrance in families (61). It has also been detected as a particularly common variant in the ExAC database (67). Neither we nor others have observed a prelamin A cleavage defect in patient cells bearing this mutation (63, 68), although we did observe a partial cleavage defect for R644 C in a mammalian expression system where the amount of available substrate is difficult to control (63). In the present study, R644 C shows approximately 80% cleavage efficiency compared with WT (Figs. 2B and 4). The impact of R644 C on prelamin A processing, and whether the associated disease phenotypes are due to an accumulation of prelamin A in cells of patients harboring this mutation, remains unclear. R644H has also been reported to be associated with disease, but disease causality has not been proven (69). In our study this R644H amino acid change did not affect processing. Overall, the findings for changes in residue R644 (position P3) are ambiguous in contrast to the L647R (position P1’) mutations, where we see a severe processing defect and cells from a MAD-B R644 C patient have been shown to exhibit a strong accumulation of prelamin A (62).

There are limitations in this study. The assay we used here reports steady-state cleavage efficiency in whole-cell lysates and does not measure the rates of processing of prelamin A variants by ZMPSTE24. Also, this assay does not ascertain the exact cleavage site, although gel migration of the cleaved product is consistent with cleavage occurring at or near the predicted cleavage site (SY1LL). Mutation of a protease cleavage recognition sequence can result in shifting the cleavage site, and we cannot exclude this possibility for our mutants that show successful cleavage. Furthermore, additional experimentation may reveal subsite cooperativity for ZMPSTE24, whereby combining multiple mutations that initially do not conform to our heatmap could be cleaved, as in the case for the HIV-1 protease and others (64–66, 70). In any case, because of the importance of ZMPSTE24 cleavage in human health and disease, gaining a better understanding of how this enzyme selects its substrates can contribute to our understanding both of progeroid diseases and also the normal physiological process of aging.

**Experimental procedures**

**Yeast strains used in this study**

The yeast strain SM4826 (ste24Δ::kanMX his3 leu2 met15 ura3) contains a deletion of the STE24 gene and is from the BY4741 deletion collection (71). Strain SM6303 (ste24Δ:: KanMX TRPI::Pfgk1-His10-HA3-ZMPSTE24) was used as the recipient strain for plasmids containing mutant forms prelamin A and analyzing their cleavage efficiency. It is derived from strain SM4826 and contains two copies of human ZMPSTE24 (codon optimized for yeast (72)) integrated into the genome at the TRPI locus (59).

**LMNA plasmids and mutagenesis**

All LMNA mutants in this study are variants of plasmid pSM3393, a centromeric HIS3 plasmid derived from pRS313 (73). In pSM3393 (shown in Fig. 1), the human prelamin A C-terminal tail (LMNACT; corresponding to amino acids 431–664 of prelamin A) is N-terminally tagged with His10 myc3 and is expressed from the PRC1 promoter (59). The collection of 152 LMNA substitution mutants and six multispecies variants assayed in this study were generated by QuikChange mutagenesis (Stratagene, San Diego, CA) with degenerate oligonucleotides or, when necessary, by individual mutagenic PCR reactions combined with NEBuilder HiFi Assembly (New England Biolabs, Ipswich, MA). Plasmid pSM3393 was the template for all reactions. For QuikChange mutagenesis, antiparallel oligonucleotides were designed to contain a degenerate codon, NNK (N represents G, T, A, or C and K represents G or T), at the target codon. Mutagenic QuikChange reactions were performed on template plasmids that had been deleted for the target codon, to reduce the incidence of wild-type amplification products. QuikChange reactions were DpnI-treated, transformed into NEB 5-alpha competent E. coli cells, and selected on carbenicillin-containing LB media. Plasmid DNA was prepared from individual colonies and individual mutations were identified and confirmed by Sanger sequencing.

For each position (P4–P4’; prelamin A residues 643–650), nearly all amino acid substitutions were generated by the degenerate oligonucleotide approach. However, when a particular mutation was missing after degenerate oligonucleotide mutagenesis, antiparallel QuikChange primers were individually designed and used with outside primers to generate mutation-containing PCR products for *in vitro* assembly with the pSM3393 backbone. The combination of degenerate oligonucleotide mutagenesis and individual PCR-based mutagenesis yielded the complete collection of 152 lamin A cleavage site mutants. The multispecies variants analyzed in Figure 6 were made by QuikChange mutagenesis, using antiparallel oligonucleotides designed to contain the multiple substitutions of each species’ putative lamin A cleavage site.

The WT LMNACT and 152 LMNACT variants on pSM3393 were individually transformed into the yeast strain SM6303, (or in some cases SM4826), by standard lithium acetate protocols, selected on minimal SC-His plates, and transformants were restreaked to isolate single colonies.

**Prelamin A cleavage assay**

Overnight cultures were grown at 30 °C to saturation in minimal medium (0.67% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, supplemented with amino acids), back diluted 1:1000, and cells were grown for 14–16 h to an OD600 of approximately 1.0. Cells (1.0 OD600 cell equivalents) were pelleted, washed with water, treated with 0.1 N NaOH, and lysed in SDS-PAGE sample buffer at 65° C for 10 min (74). Lysates were vortexed, pelleted, and supernatants (0.24 OD600 cell equivalents per lane) were resolved on 10% SDS polyacrylamide gels for 90 min at 150V. Proteins were transferred to nitrocellulose membranes using the Trans-Blot Turbo system (Bio-Rad Laboratories, Hercules, CA) and blocked with Western Blocking Reagent (Roche, Indianapolis, IN).
Cleavage site for prelamin A processing by ZMPSTE24

Lamin A proteins were detected by probing with mouse anti-Myc antibodies (clone 4A6, Millipore cat #05–724; 1:10,000 dilution) decorated with goat anti-mouse secondary IRDye 680RD antibodies (LI-COR, Lincoln, NE). The loading control hexokinase was detected using and rabbit anti-hexokinase (1:200,000 dilution) antibodies decorated with goat anti-rabbit secondary IRDye 800CW (LI-COR) antibodies. Western blots were visualized using the Odyssey imaging platform (LI-COR) and bands were quantified using Image Studio software (LI-COR). Cleavage efficiency was calculated by dividing mature lamin A signal by total lamin A signal (processed + unprocessed) and normalized to WT processing efficiency, which was set to 1.0. Cleavage assays were performed as three independent biological replicates. Blots were reprobed using rat anti-HA (clone 3F10, Roche cat #11867423001; 1:10,000 dilution) to detect ZMPSTE24 and visualized using goat anti-rat IRDye 680RD.

Multispecies alignment

Protein sequences for the species studied were acquired from UniProt (UniProt Consortium, 2017) and aligned using ClustalX (75). Putative cleavage sites for divergent species were inferred from the alignment and introduced into pSM3393 via mutagenic PCR and assembled as described above. Resulting constructs were transformed into yeast strains SM6303 and SM4826 and assayed for prelamin A cleavage as described above.

Data availability

All data are contained within the article.

Acknowledgements—We thank Mark Dumont (University of Rochester) for providing a yeast codon-optimized version of human ZMPSTE24. We thank Kaitlin Wood and Khurts Shilagardi, members of the Michaelis lab for comments on the manuscript and Ashley Pike in the Carpenter lab for help with Figure 6.

Author contribution—S. M. and T. D. B. conceptualization; S. M. and T. D. B. supervision; T. D. B., W. X., O. L. S. experimental investigation; S. M., T. D. B., L. N., and E. P. C. formal analysis; T. D. B., E. D. S. and S. M. methodology; T. D. B., E. D. S., and S. M. writing—original draft; S. M. and T. D. B. project administration; S. M. and E. P. C. funding acquisition.

Funding and additional information—This work was funded by a National Institutes of Health (NIH) grant to SM (5R35GM127073) and a Medical Research Council grant (MR/L017458/1) to EPC. LN and EPC are funded by the Structural Genomics Consortium (SGC). The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Genome Canada, Janssen, Lilly Canada, Merck KGaA, Merck & Co, Novartis, the Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP and Takeda, as well as the Innovative Medicines Initiative Joint Undertaking ULTRA-DD grant 115766 and the Wellcome Trust (106169/Z/14/Z).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: HGPS, Hutchinson–Gilford progeria syndrome; MAD-B, mandibuloacral dysplasia type-B; RD, restrictive dermopathy; WT, wild-type.

References

1. Lopez-Otin, C., and Bond, J. S. (2008) Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283, 30433–30437
2. Turk, B., Turk, D., and Turk, V. (2012) Protease signalling: the cutting edge. EMBO J. 31, 1630–1643
3. Bergo, M. O., Gavino, B., Ross, J., Schmidt, W. K., Hong, C., Kendall, L. V., Mohr, A., Meta, M., Genant, H., Jiang, Y., Wiener, E. R., Van Bruggen, N., Carano, R. A., Michaelis, S., Griffe, S. M., et al. (2002) Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U. S. A. 99, 13049–13054
4. Buttin-Israeli, V., Adam, S. A., Goldman, A. E., and Goldman, R. D. (2012) Nuclear lamin functions and disease. Trends Genet. 28, 464–471
5. Dittmer, T. A., and Misteli, T. (2011) The lamin protein family. Genome Biol. 12, 222
6. Gerace, L., and Huber, M. D. (2012) Nuclear lamina at the crossroads of the cytoplasm and nucleus. J. Struct. Biol. 177, 24–31
7. Gruenbaum, Y., and Foisner, R. (2015) Lamins: nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. Annu. Rev. Biochem. 84, 131–164
8. Michaelis, S., and Hrycyna, C. A. (2013) Biochemistry. A protease for the ages. Science 339, 1529–1530
9. Pendas, A. M., Zhou, Z., Cadinanos, J., Freije, J. M., Wang, J., Hultenby, K., Astudillo, A., Wernerson, A., Rodriguez, F., Tryggvason, K., and Lopez-Otin, C. (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 null mice. Nat. Genet. 31, 94–99
10. Barrowman, I., Hamblet, C., George, C. M., and Michaelis, S. (2008) Analysis of prelamin A biogenesis reveals the nuclear to be a Caax processing compartment. Mol. Biol. Cell 19, 5398–5408
11. Michaelis, S., and Barrowman, J. (2012) Biogenesis of the Saccharomyces cerevisiae pheromone a-factor, from yeast mating to human disease. Microbiol. Mol. Biol. Rev. 76, 626–651
12. Wang, M., and Casey, P. J. (2016) Protein prenylation: unique fats make their mark on biology. Nat. Rev. Mol. Cell Biol. 17, 110–122
13. Warman, H. J., Fong, L. G., Muchir, A., and Young, S. G. (2009) Lamino-pathies and the long strange trip from basic cell biology to therapy. J. Clin. Invest 119, 1825–1836
14. Vorburger, K., Kitten, G. T., and Nigg, E. A. (1989) Modification of nuclear lamin proteins by a mevalonic acid derivative occurs in reticulocyte lysates and requires the cysteine residue of the C-terminal CXXM motif. EMBO J. 8, 4007–4013
15. Weber, K., Plessmann, U., and Traub, P. (1989) Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett. 257, 411–414
16. Capell, B. C., and Collins, F. S. (2006) Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 7, 940–952
17. Davies, B. S., Fong, L. G., Yang, S. H., Coffiner, C., and Young, S. G. (2009) The posttranslational processing of prelamin A and disease. Annu. Rev. Genomics Hum. Genet. 10, 153–174
18. Dorado, B., and Andres, V. (2017) A-type lamins and cardiovascular disease in premature aging syndromes. Curr. Opin. Cell Biol. 46, 17–25
19. De Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., Boccaccio, I., Lyonnet, S., Stewart, C. L., Munnich, A., Le Merrer, M., and Levy, N. (2003) Lamin A truncation in Hutchinson-Gilford progeria. Science 305, 2055
20. Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., Erdos, M. R., Robbins, C. M., Moses, T. Y., Berglund, P., Dutra, A., Pak, E., Durkin, S., Sooka, A. B., Boehnke, M., et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293–298
Cleavage site for prelamin A processing by ZMPSTE24

21. Gordon, L. B., Rothman, F. G., Lopez-Otín, C., and Misteli, T. (2014) Progeria: a paradigm for translational medicine. *Cell* **156**, 400–407

22. Agarwal, A. K., Fryns, J. P., Auchus, R. J., and Garg, A. (2003) Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. *Hum. Mol. Genet.* **12**, 1995–2001

23. Mousson, C. L., Go, G., Gardner, J. M., van der Wal, A. C., Smitt, J. H., van Hagen, J. M., and Minner, J. H. (2005) Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. *J. Invest. Dermatol.* **125**, 913–919

24. Navarro, C. L., Cadinanos, J., De Sandre-Giovannoli, A., Bernard, R., Courrier, S., Boccaccio, L., Boyer, A., Kleijer, W. I., Wagner, A., Giuliano, F., Beemer, F. A., Freije, J. M., Cau, P., Hennekam, R. C., Lopez-Otín, C., et al. (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. *Hum. Mol. Genet.* **14**, 1503–1513

25. Navarro, C. L., Esteves-Vieira, V., Courrier, S., Boyer, A., Duong Nguyen, T., Huong Le, T. T., Meinke, P., Schroder, W., Cormier-Daire, V., Sznajder, Y., Amor, D. J., Lagerstedt, K., Biervliet, M., van den Akker, P. C., Cau, P., et al. (2014) New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update. *Eur. J. Hum. Genet.* **22**, 1002–1011

26. Smigiel, R., Jakubiai, A., Esteves-Vieira, V., Szela, K., Halon, A., Jurek, T., Levy, N., and De Sandre-Giovannoli, A. (2010) Novel frameshifting mutations of the ZMPSTE24 gene in two siblings affected with restrictive dermopathy and review of the mutations described in the literature. *Am. J. Med. Genet. A* **152A**, 447–452

27. Barrowman, J., Wiley, P. A., Hudon-Miller, S. E., Hrycyna, C. A., and Michaelis, S. (2012) Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. *Hum. Mol. Genet.* **21**, 4084–4093

28. Spear, E. D., Hsu, E. T., Nie, L., Carpenter, E. P., Hrycyna, C. A., and Michaelis, S. (2018) ZMPSTE24 missense mutations that cause progeroid diseases decrease prelamin A cleavage activity and/or protein stability. *Dis. Model. Mech.* **11**

29. Ragnauth, C. D., Warren, D. T., Liu, Y., McNair, R., Tajiss, T., Figg, N., Shroff, R., Skepper, J., and Shanahan, C. M. (2010) Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* **121**, 2200–2210

30. Pryor, E. E., Jr., Horanyi, P. S., Clark, K. M., Fedorin, N., Connelly, S. M., Koszelak-Rosenblum, M., Zhu, G., Malkowski, M. G., Wiener, M. C., and Dumont, M. E. (2013) Structure of the integral membrane protein CAAX protease Ste24p. *Science* **340**, 1600–1604

31. Quigley, A., Dong, Y. Y., Pike, A. C., Dong, L., Shrestha, L., Berridge, G., Stansfeld, P. J., Sansom, M. S., Edwards, A. M., Bountra, C., von Delft, F., Ward, A. C., Smitt, J. H., van Hagen, J. M., and Miner, J. H. (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal recessive dermopathy. *J. Invest. Dermatol.* **124**, 969–977

32. Krohne, G., Waizenegger, I., and Hoger, T. H. (1989) The conserved CaaX motif of lamin A functions in conjunction with the nuclear localization signal to target assembly to the nuclear envelope. *Cell* **109**, 2003–2011

33. Mallampalli, M. P., Huyer, G., Bendale, P., Gelb, M. H., and Michaelis, S. (2005) Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 14416–14421

34. Sinensky, M., Fantle, K., Trujillo, M., McLain, T., Kupfer, A., and Dalton, M. (1994) The processing pathway of prelamin A. *J. Cell Biol.* **107**(Pt 1), 61–67

35. Hildebrandt, E. R., Arachea, B. T., Wiener, M. C., and Schmidt, W. K. (2016) Ste24p mediates proteolysis of both Isoprenylated and non-isoprenylated Oligopeptides. *J. Biol. Chem.* **291**, 14185–14198

36. Ast, T., Michaelis, S., and Schuldiner, M. (2016) The protease Ste24 clears clogged translocons. *Cell* **164**, 103–114

37. Kayatekin, C., Amasino, A., Gagli, G., Flannick, J., Bonner, J. M., Fanning, S., Narayan, P., Barrasa, M. I., Pincus, D., Landgraf, D., Nelson, J., Hesse, W. R., Costanzo, M., Consortium, A. T. D. G., Myers, C. L., et al. (2018) Translocon Declogger Ste24 Protects against IAPP Oligomer-Induced Proteotoxicity. *Cell* **173**, 62–73; e69

38. Hosomi, A., Iida, K., Cho, T., Iida, H., Kaneko, M., and Suzuki, T. (2020) The ER-associated protease Ste24 prevents N-terminal signal peptide-independent translocation into the ER in Saccharomyces cerevisiae. *J. Biol. Chem.* **295**, 10406–10419

39. Fu, B., Wang, L., Li, S., and Dorf, M. E. (2017) ZMPSTE24 defends against influenza and other pathogenic viruses. *J. Exp. Med.* **214**, 919–929

40. Li, S., Fu, B., Wang, L., and Dorf, M. E. (2017) ZMPSTE24 is Downstream effector of Interferon-Induced transmembrane Antiviral activity. *DNA Cell Biol.* **36**, 513–517

41. Hennekens, H., and Nigg, E. A. (1994) The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. *J. Cell Sci.* **107**(Pt 4), 1019–1029

42. Turk, B. E., Huang, L. L., Piro, E. T., and Cantley, L. C. (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. *Nat. Biotechnol.* **19**, 661–667

43. Vilmar, R., Vizovisek, M., Turk, D., Turk, B., and Fonovic, M. (2017) Protease cleavage site fingerprinting by label-free in-gel degradomics reveals pH-dependent specificity switch of legumain. *EMBO J.* **36**, 2455–2465
Cleavage site for prelamin A processing by ZMPSTE24

59. Spear, E. D., Alford, R. F., Babatz, T. D., Wood, K. M., Mossberg, O. W., Odinammadu, K., Shilagardi, K., Gray, J. J., and Michaelis, S. (2019) A humanized yeast system to analyze cleavage of prelamin A by ZMPSTE24. *Methods* **157**, 47–55

60. Schechter, I., and Berger, A. (1967) On the size of the active site in proteases. *Papain. Biochem. Biophys. Res. Commun.* **27**, 157–162

61. Rankin, J., Auer-Grumbach, M., Bagg, W., Colclough, K., Nguyen, T. D., Fenton-May, J., Hattersley, A., Hudson, J., Jardine, P., Josifova, D., Longman, C., McWilliam, R., Owen, K., Walker, M., Wehnert, M., *et al.* (2008) Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. *Am. J. Med. Genet. A.* **146A**, 1530–1542

62. Wang, Y., Lichter-Konecki, U., Anyane-Yeboa, K., Shaw, J. E., Lu, J. T., Ostlund, C., Shin, J. Y., Clark, L. N., Gunderson, G. G., Nagy, P. L., and Worman, H. J. (2016) A mutation abolishing the ZMPSTE24 cleavage site in prelamin A causes a progeroid disorder. *J. Cell Sci.* **129**, 1975–1980

63. Barrowman, J., Hamblet, C., Kane, M. S., and Michaelis, S. (2012) Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. *PLoS One* **7**, e32120

64. Boyd, S. E., Kerr, F. K., Albrecht, D. W., de la Banda, M. G., Ng, N., and Pike, R. N. (2009) Cooperative effects in the substrate specificity of the complement protease C1s. *Biol. Chem.* **390**, 503–507

65. Ng, N. M., Pike, R. N., and Boyd, S. E. (2009) Subsite cooperativity in protease specificity. *Biol. Chem.* **390**, 401–407

66. Ridky, T. W., Cameron, C. E., Cameron, J., Leis, J., Copeland, T., Wlodawer, A., Weber, I. T., and Harrison, R. W. (1996) Human immuno-deficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites. *J. Biol. Chem.* **271**, 4709–4717

67. Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., Cummings, B. B., Tukianen, T., Birnbaum, D. P., Kosmicki, J. A., Duncan, L. E., Estrada, K., *et al.* (2016) Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291

68. Toth, J. I., Yang, S. H., Qiao, X., Beigneux, A. P., Gelb, M. H., Moulong, C. L., Miner, J. H., Young, S. G., and Fong, L. G. (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 12873–12878

69. Mercuri, E., Brown, S. C., Nihoyannopoulos, P., Poulton, J., Kinali, M., Richard, P., Piercy, R. J., Messina, S., Sewry, C., Burke, M. M., McKenna, W., Bonne, G., and Muntoni, F. (2005) Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. *Muscle Nerve* **31**, 602–609

70. Schilling, O., and Overall, C. M. (2008) Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. *Nat. Biotechnol.* **26**, 685–694

71. Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., Chu, A. M., Connelly, C., Davis, K., Dietrich, F., Dow, S. W., *et al.* (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. *Science* **285**, 901–906

72. Clark, K. M., Jenkins, J. L., Fedoriw, N., and Dumont, M. E. (2017) Human CaaX protease ZMPSTE24 expressed in yeast: structure and inhibition by HIV protease inhibitors. *Protein Sci.* **26**, 242–257

73. Sikorski, R. S., and Hieter, P. (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. *Genetics* **122**, 19–27

74. Kushnirov, V. V. (2000) Rapid and reliable protein extraction from yeast. *Yeast* **16**, 857–860

75. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., and Higgins, D. G. (2007) Clustal W and Clustal X version 2.0. *Bioinformatics* **23**, 2947